Smirnoff switches over to Weber's health practice

Share this article:
Smirnoff switches over to Weber's health practice
Smirnoff switches over to Weber's health practice

PR firm Weber Shandwick announced Susan Smirnoff will join the agency's health practice as EVP/senior counselor.

Smirnoff joins Weber from another New York-based shop, Ruder Finn, where she had spent 33 years and co-led the agency's US healthcare practice. She also had worked as a senior counselor in the agency's healthcare and corporate communications teams.

The veteran counselor brings deep experience in oncology and neuroscience to her new role. In a statement, Laura Schoen, president of Weber Shandwick's global healthcare practice, hailed Smirnoff's "passion for science" and "commitment to delivering programs that impact patient outcomes."

The hire follows last month's news that the US Department of Health and Human Services (HHS) added $33 million to Weber's contract in an effort to further awareness for state health insurance exchanges, according to a report from PRWeek (sub req'd).  

Earlier this year, Weber was also awarded a contract from Covered California—the organization which runs that state's health insurance exchange. The $12-million contract includes creative development, social media and collateral materials through April 2015.

In May, Weber added a healthcare specialty shop to its offerings, Element Scientific Communications.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...